Researchers are making strides in understanding profound autism by studying protein interactions in lab-grown brain tissues, known as organoids. These breakthroughs aim to uncover how gene mutations contribute to autism.
A study conducted at UC San Francisco has mapped over a thousand interactions between proteins linked to autism risk genes. Published in Science, this molecular atlas represents a significant resource for future research and treatment development.
Innovative Approach
Collaborators Nevan Krogan and Dr. Matthew State combined their expertise to bridge the gap between genetic discoveries and potential treatments. Identifying hundreds of genes with mutations in individuals with profound autism, they sought to understand how these mutations affect protein functionality.
In the research, they pinpointed protein interactions by introducing 100 proteins from high-risk autism genes into lab-grown cells. Using artificial intelligence, specifically Google’s AlphaFold, researchers predicted interactions among these proteins.
Protein Interactions as Key Insights
The study assessed how mutations disrupt protein functions. Researchers simulated these mutations in frogs and organoids, observing changes in protein behavior. They noted alterations in protein connections that led to neurodevelopmental defects.
Said Dr. Daniel Geschwind of UCLA, many mutations converge on the same biological pathways, particularly ones crucial for early brain development. This convergence suggests that shared protein pathways might provide potential targets for treatment.
Potential Impact on Drug Development
Developing treatments based on these findings will be a long-term process, requiring evaluation of drug candidates for safety and efficacy. Most drugs target protein interactions, suggesting this research could be pivotal for pharmaceutical advancements.
Funded by Sergey Brin’s grant from the Aligning Research to Impact Autism initiative, further efforts aim to expedite drug development through technological advances, including AI.
“This [paper] is unlikely to lead to therapies tomorrow — but it lays an important foundation for them.” — Dr. Matthew State